Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

ABSTRACT:

Importance

Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.

Objectives

To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival.

Design, setting, and participants

From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through

SUBMITTER: Kris MG 

PROVIDER: S-EPMC4163053 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature